Noel Barrett

Noel Barrett is a distinguished business leader in the field of vaccines. He has more than 30 years of experience in the vaccine and biologics industry, with management responsibilities covering the complete development process required to bring vaccine products to the market. In his prior position as Vice President Global Research and Development Vaccines at Baxter Healthcare, he led the development and licensure of Baxter’s FSME tick-borne encephalitis vaccine, Meningococcal C vaccine, and cell‑culture derived H5N1, H1N1, and seasonal influenza vaccines (Preflucel®). His contribution to the Baxter scientific community was recognized with the title of Baxter Distinguished Scientist, the most prestigious scientific recognition within the company, and the Baxter Bioscience President’s Leadership Award.

Dr. Barrett was CEO of AFFiRiS AG for a three year period up to April 2022. During this period he was instrumental in managing the sale of the alpha-synuclein and beta-amyloid neurodegenerative disease assets to AC Immune. He also managed the resulting restructuring process, the establishment of the AFFiRiS CVD GmbH company spin- off and the negotiation of the co-development partnership for the cardiovascular PCSK9 program with Frontier Biotechnologies.